基本信息 产品详情 公司简介 推荐产品
  • 首页
  • 个人中心
  • 委托采购
  • 采购清单
网站主页 CP-610431 CP-610431
  • CP-610431|T40675|TargetMol

CP-610431|T40675|TargetMol

CP-610431
591778-83-5
￥10600 25mg 起订
上海 更新日期：2025-11-17

TargetMol中国（陶术生物）

VIP2年
联系人：邵小姐
手机：15002134094 拨打
邮箱：marketing@targetmol.cn

产品详情:

中文名称：
CP-610431
英文名称：
CP-610431
CAS号：
591778-83-5
品牌：
TargetMol
产地：
美国
保存条件：
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
产品类别：
抑制剂
货号：
T40675

Product Introduction

Bioactivity

名称CP-610431
描述CP-610431 is a reversible, ATP-uncompetitive inhibitor of acetyl-CoA carboxylase (ACC), exhibiting isozyme nonselectivity. It inhibits both ACC1 and ACC2 with IC50 values of approximately 50 nM. CP-610431 offers potential application in metabolic syndrome research.
体外活性CP-610431 is the active R-enantiomer of CP-497485. CP-610431 is more potent than the racemate CP-497485 in inhibiting rat ACC1 (IC 50 =35.7 nM) and ACC2 (IC 50 =55 nM), whereas the?S-enantiomer, CP-610432, does not substantially inhibit either ACC isoform at concentrations of up to 3 μM. CP-610431 is more potent than CP-497485 in inhibiting HepG2 cell fatty acid and triglyceride (TG) synthesis and in inhibiting TG and apoB secretion[1]. CP-610431 inhibits fatty acid synthesis, triglyceride synthesis, TG secretion, and apolipoprotein B secretion in HepG2 cells (ACC1) with EC 50 s of 1.6, 1.8, 3.0, and 5.7 μM, without affecting either cholesterol synthesis or apolipoprotein CIII secretion[1]. CP-610431 inhibits both liver and skeletal muscle ACC activity from all three species with essentially equal potency (rat, 36?versus?55 nM; mouse, 50?versus?63 nM; cynomolgus macaque, 70?versus?26 nM)[1]. CP-610431 inhibits mouse primary hepatocyte fatty acid and TG synthesis with IC 50 values of 0.11 and 1.2 μM?and inhibits TG secretion with an IC 50 of 10 μM[1]. Cell Viability Assay[1]Cell Line: HepG2 cells Concentration: 0.1, 1, 10 μM Incubation Time: 24 hours Result: Dose-dependently inhibited HepG2 cell fatty acid synthesis with an IC 50 of 1.6 μM, TG synthesis with an IC 50 of 1.8 μM, TG secretion with an IC 50 of 3.0 μM, and apoB secretion with an IC 50 of 5.7 μM.
体内活性CP-610431 inhibits fatty acid synthesis in CD1 mice and ob/ob mice within 1 h after dose with ED 50 s of 22 and 4 mg/kg,?respectively[1]. Animal Model: CD1 mice[1]Dosage: 30 and 100 mg/kg for fasting CD1 mice; 10, 30, and 100 mg/kg for non-fasting CD1 mice Administration: Intraperitoneal administration; 1 hour Result: Inhibited hepatic fatty acid synthesis in fasting CD1 mice by 64±12%, and 77±4% at doses of 30 and 100 mg/kg, respectively. Inhibited hepatic fatty acid synthesis in non-fasting CD1 mice by 18%, 51%, and 75% at doses of 10, 30 and 100 mg/kg, respectively.
存储条件Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
关键字CP-610431 | CP610431 | CP 610431
相关产品TOFA | ND-646 | Acetyl-CoA Carboxylase-IN-1 | PF-05175157 | Firsocostat | Clodinafop-propargyl | PF-05221304 | CMS-121 | Olumacostat Glasaretil | Quizalofop-ethyl | Moiramide B | Quizalofop-p-ethyl
CP-610431|TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。 凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期 (13年)
注册资本 589.8595万人民币
员工人数 100-500人
年营业额 ￥ 1亿以上
经营模式 贸易,工厂,试剂,定制,服务
主营行业 中间体,天然产物,生物化工,化学试剂,生物技术服务

CP-610431相关厂家报价

内容声明
official 进入官方账号
拨打电话 立即询价